Pregnancy, Thrombophilia, and the Risk of a First Venous Thrombosis: Systematic Review and Bayesian Meta-Analysis

Abstract

Women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden should be considered for antepartum or postpartum thrombosis prophylaxis, or both. Women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A mutation should generally not be prescribed thrombosis prophylaxis based on thrombophilia and family history alone. These data should be considered in future guidelines on pregnancy associated VTE risk.